JYLDYZ TEMIRKAN: Open Payments
NPI 1497463715 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 36 payments from 14 companies in 2025. Trend: 2023 $230 · 2024 $969 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 16 | $229 |
| AstraZeneca Pharmaceuticals LP | 2 | $175 |
| Dexcom, Inc. | 3 | $69 |
| Lilly USA, LLC | 2 | $63 |
| Novo Nordisk Inc | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $30 |
| Phadia US Inc. | 2 | $28 |
| Edwards Lifesciences Corporation | 1 | $23 |
| Abbott Laboratories | 1 | $21 |
| ABBVIE INC. | 1 | $21 |
Products named: REPATHA, AIRSUPRA, OTEZLA, Dexcom G6 Transmitter, BREZTRI, JARDIANCE, ImmunoCAP, Ozempic.
Industry payments across AZ — which companies pay providers there.
